Trust Point Inc. Buys Shares of 8,836 Edwards Lifesciences Corporation $EW

Trust Point Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, HoldingsChannel reports. The fund bought 8,836 shares of the medical research company’s stock, valued at approximately $687,000.

Other large investors also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Rosenberg Matthew Hamilton acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $28,000. NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Rakuten Securities Inc. boosted its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Finally, Riverview Trust Co grew its stake in shares of Edwards Lifesciences by 44.5% in the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $85.66 on Friday. The company has a 50-day moving average of $82.53 and a 200-day moving average of $79.28. The firm has a market cap of $49.71 billion, a price-to-earnings ratio of 36.92, a price-to-earnings-growth ratio of 3.85 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,848,828.06. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 45,465 shares of company stock worth $3,804,610. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on EW shares. Robert W. Baird set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “neutral” rating in a research note on Tuesday. Barclays reissued an “overweight” rating and set a $103.00 target price (up previously from $99.00) on shares of Edwards Lifesciences in a research note on Monday, December 8th. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a report on Thursday. Finally, National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.